Lupus Science & Medicine

Frequency and associated factors of herpes zoster infection in SLE patients from Latin America: data from the GLADEL 2.0 cohort

Objective The aim of this study was to assess the epidemiological and clinical characteristics of herpes zoster (HZ) and to ...
Lupus Science & Medicine

Long-term outcomes of hydroxychloroquine dose reduction in Puerto Ricans with systemic lupus erythematosus: 6-year follow-up

Background/objective To reduce the risk of hydroxychloroquine (HCQ)-induced retinopathy, the American Academy of ...
Lupus Science & Medicine

‘Getting comfortable with the uncomfortable’: barriers, facilitators and influences on reproductive health discussions from Hispanic women with systemic lupus erythema…

Objective Systemic lupus erythematosus (SLE) primarily affects women of reproductive age, necessitating complex conversations ...
lupus.bmj

PT7:02 Discordance between SLEDAI-2K and BILAG-2004 disease activity classification leads to divergent treatment decisions under EULAR 2023 recommendations: a post-hoc analysis ...

Objectives The 2023 EULAR recommendations for the management of SLE endorse stratifying disease activity into mild, moderate, and severe categories to guide treat-to-target (T2T) strategies. Both ...
lupus.bmj

PO:12:326 Developing two distinct organoid-based models to study failing maternal-fetal tolerance in systemic lupus erythematosus

Objectives Up 50% of pregnancies in women with systemic lupus erythematosus (SLE) is complicated by adverse outcomes, such as preterm birth, fetal growth restriction and pre-eclampsia. The underlying ...
lupus.bmj

Lupus Science & Medicine®

is a global, peer-reviewed, open access lupus journal from LFA, publishing papers on all aspects of lupus and related diseases.
lupus.bmj

Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort

Objective To evaluate the efficacy of mepacrine (MC) as an add-on therapy in patients with SLE unresponsive to hydroxychloroquine (HCQ)-containing regimens at 6 months after MC introduction. Methods ...
Lupus Science & Medicine

Risk factor of osteoporosis in systemic lupus erythematosus patients: a cross-sectional study in a tertiary hospital in Indonesia

Introduction Osteoporosis and fragility fracture are more frequently found in systemic lupus erythematosus (SLE) patients ...
lupus.bmj

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III ...

Objective To assess the appropriateness of expanded serological activity eligibility criteria for belimumab use in the UK systemic lupus erythematosus (SLE) population (and possibly other countries), ...
lupus.bmj

617 Doing everything possible to prioritize work: lived work experience of young adults with systemic lupus erythematosus

Background Young adulthood (18–30 years) is a critical life-stage when individuals launch into independence, establishing employment. Failure to establish employment during young adulthood is ...
lupus.bmj

PO:01:015 Thromboangiitis obliterans in antiphospholipid syndrome and treatment

Objectives To present a clinical case of two patients with resistant thromboangiitis obliterans, as a manifestation of antiphospholipid syndrome (APS), successfully treated with rituximab. Methods Two ...
lupus.bmj

LSO-001 Modulating T-bet-promoted energy metabolism in pathogenic age/autoimmune-associated B cells ameliorates lupus autoimmunity

Background Emerging evidences indicate that a distinct CD11c+T-bet+ B cell subset termed age/autoimmune-associated B cells (ABCs) is the major pathogenic autoantibody producer in lupus. Human lupus is ...